The AFL-AGC Building Trades Welfare plan alleges that Pfizer and Ranbaxy delayed a generic version of Lipitor for 20 months. The plan has brought a proposed class-action lawsuit in U.S. District Court, Southern District of New York (Manhattan). Plaintiffs claim that Ranbaxy, the manufacturer of the generic, entered into an anticompetitive scheme with Pfizer, whose patent for Lipitor expired on March 24, 2010.
Related content: Reversing the Trend? The Possibility that Rule Changes May Lead to Fewer Reverse Payments in Pharma Settlements (Anne Layne-Farrar, Compass Lexecon)